(Q53472905)

14 May 2018

title

Health-related quality of life with coronary heart disease prevention and treatment. (English)

1 reference

14 May 2018

1 reference

1 reference

1 reference

coronary artery disease

1 reference

L Lalonde

1

1 reference

14 May 2018

A E Clarke

2

1 reference

14 May 2018

L Joseph

3

1 reference

14 May 2018

T Mackenzie

4

1 reference

14 May 2018

S A Grover

5

1 reference

14 May 2018

Canadian Collaborative Cardiac Assessment Group

6

1 reference

14 May 2018

publication date

1 October 2001

1 reference

14 May 2018

Journal of Clinical Epidemiology

published in

1 reference

14 May 2018

volume

54

1 reference

14 May 2018

issue

10

1 reference

14 May 2018

page(s)

1011-1018

1 reference

14 May 2018

Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Cost effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin versus cholestyramine

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Cost-effectiveness of interventions to prevent or treat coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Comparison of an Aggressive (U.S.) and a Less Aggressive (Canadian) Policy for Cholesterol Screening and Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Psychologic effects of the diagnosis and treatment of hypercholesterolemia: Lessons from case studies

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Does cholesterol screening result in negative labeling effects? Results of the Massachusetts Model Systems for Blood Cholesterol Screening Project

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Is knowing your cholesterol number harmful?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Health status and hypertension: a population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Outcomes of total hip and knee replacement: preoperative functional status predicts outcomes at six months after surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Pitfalls in the serial assessment of cardiac functional status. How a reduction in "ordinary" activity may reduce the apparent degree of cardiac compromise and give a misleading impression of improvement

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Comparing the psychometric properties of preference-based and nonpreference-based health-related quality of life in coronary heart disease. Canadian Collaborative Cardiac Assessment Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Conventional and chained standard gambles in the assessment of coronary heart disease prevention and treatment. Canadian Collaborative Cardiac Assessment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Functional status versus utilities in survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

Selection of end points in economic evaluations of coronary-heart-disease interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2801%2900361-4

7 January 2021

10.1016/S0895-4356(01)00361-4

Identifiers

DOI

1 reference

14 May 2018

PubMed ID

11576812

1 reference

14 May 2018